Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, prevalent hemodialysis patients~* Informed and consented~* Hemodialysis 3x/week via a tunneled cuffed catheter~* Urokinase administration at least two times during the previous 6 months (with more than a week between 2 administrations)~* Adequate catheter function during the week before inclusion (defined by blood flow more than 250ml/min on each dialysis session and blood flow within 15% of the maximal blood flow after the last Urokinase administration)~Exclusion Criteria:~* Presence of heparin-induced thrombocytopenia~* Major hemorrhage or intracranial bleeding in the previous 3 months~* Pericarditis~* Intolerance to Taurolidine, citrate or to Urokinase~* Active catheter-related infection~* Catheter in the femoral vein

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Taurolidine Urokinase (Type: EXPERIMENTAL): Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
- Taurolidine Heparin (Type: ACTIVE_COMPARATOR): Taurolock HEP 500 is used as locking solution after each dialysis session

Based on this trial design, predict the completion outcome and termination type (if applicable).